Home
Controlled Release
12 March - 13 March 2014
Controlled Release

Controlled release remains one of the most important innovate areas in pharma, with revenues set to dramatically increase to 2020. Recent advances in drug delivery systems have created the perfect mix for opportunities in the field.

SAE Media Group is proud to present its 11th annual controlled release conference, held in central London on the 12 & 13 March 2014. The meeting will continue in a long tradition of critically acclaimed speakers who are pioneers in their field. This event offers you a unique opportunity to keep up to date with the latest in technologies and methods such as the diffusion of nanomaterials through biological and non-biological gels.
 

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Howard Stevens

Howard Stevens, Professor, University Of Strathclyde

clock

9:10

Setting Specifications for Controlled Release Products: A Statistically Based Approach

David Elder

David Elder, Externalisation Director, GlaxoSmithKline Research & Development

  • Role of dissolution testing
  • Evolution of pharmacopoeial specifications for dissolution testing
  • Specification requirements;
  • Bio pharmaceutics
  • Sampling intervals
  • IVIVC / No IVIVC
  • ICH Decision Tree
  • Statistical Evaluation;
  • Approach of Sathe (90% confidence ellipses)
  • Box and Whisker plots
  • Interactions with FDA
  •  

    clock

    9:50

    Overcoming the impact of the GI tract in oral formulation design

    Howard Stevens

    Howard Stevens, Professor, University Of Strathclyde

  • GI tract physiology, pH, motility and dosage form transit
  • Visualisation of dosage forms in man
  • Design of formulations to be independent of patient factors
  • clock

    10:30

    Morning Coffee

    clock

    10:50

    Oral drug delivery technology- the challenges an industrial and academic perspective

    Luigi Martini

    Luigi Martini, Professor of Pharmaceutical Innovation, Kings College London

  • Why are oral drug delivery systems so important to pharmaceutical industry and to medical science?
  • Why is there a paucity of new systems and drug delivery companies investing in drug delivery technology?
  • What are the challenges to their development?
  • What are the possible solutions?
  • clock

    11:30

    Best pre-formulation strategies for troublesome compounds in early development

    Duk Soon Choi

    Duk Soon Choi, Vice President Preformulation, Kashiv Pharma

  • Understanding drug like properties of molecules to be successful medicine
  • Strategies in selection of the right molecules for clinics
  • Tools and means to overcome limitations
  • Early toxicology enabling formulation strategies for poorly soluble compounds
  • Amorphous formulation development strategies
  • clock

    12:10

    Networking Lunch

    clock

    13:30

    Approaches to improve bioavailability of drugs topically administered to the eye

    Vitaliy  Khutoryanskiy

    Vitaliy Khutoryanskiy, Reader in Pharmaceutical Materials, University of Reading

  • Anatomical and physiological considerations of ocular route of drug administration
  • Approaches to improve corneal permeability
  • Approaches to improve pre-corneal retention
  • In vitro and in vivo methodologies for testing
  • clock

    14:10

    Drug Delivery and Sustained Release. How hard can it be?

    Dr Andrew Naylor PhD MRSC

    Dr Andrew Naylor PhD MRSC, Head of Process Development, Critical Pharmaceuticals Limited

  • Challenges of producing sustained release formulations
  • Using CriticalMix, a novel manufacturing method to overcome the problems
  • Improve compliance by ensuring the final product is easy to use and well tolerated
  • clock

    14:50

    Afternoon Tea

    clock

    15:10

    Latest trends in drug delivery

    Tugrul Kararli

    Tugrul Kararli, President, Founder, Pharmacircle

  • Drug Delivery (DD) technologies and formulations
  • Life Cycle Management
  • Pipeline and products using DD technologies
  • Deals/Acquisitions/Investments
  • Unmet needs and future
  • clock

    15:50

    Bacteriophage: from phage therapy to delivery systems of therapeutics in other human diseases

    Amin Hajitou

    Amin Hajitou, Senior Lecturer and Principal Investigator , Imperial College London

  • Bacteriophage-guided gene transfer in gene therapy and DNA vaccine
  • Advantages of using bacteriophage to existing drug delivery systems
  • Bacteriophage as advanced functional biomaterials
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Joel Richard

    Joel Richard, Vice President Peptides , IPSEN

    clock

    9:10

    Peptide Delivery: What Is the Present Status and What Does the Future Hold?

    Joel Richard

    Joel Richard, Vice President Peptides , IPSEN

  • Understanding the importance of peptides  as a fast growing drug class and the prime focus in formulation and delivery
  • Exploring the global picture of peptide delivery  
  • What developments are made currently in the field of injectable sustained release forms of peptides?
  • What is the next generation of peptide delivery? – oral, transdermal, . . .  opportunities
  • Applying Ipsen technology platform to support long acting  peptide formulations - Case Study: Injectable self-assembling lanreotide
  • clock

    9:50

    Creating extended half-life peptide therapeutics using AlbudAbsTM

    Oliver  Schon

    Oliver Schon, Group Leader, NBE Profiling & Analysis, Biopharm Innovation, BIOpharm, GlaxoSmithKline

  • Update on the preclinical and clinical data of domain antibody-based drugs that are currently in clinical development
  • Library design, lead discovery process/engineering
  • Selection of formats for improved biological, biophysical and pharmacokinetic properties, focussing on the half-life extension technology platform
  • clock

    10:30

    Morning Coffee

    clock

    10:50

    Defining and Attaining Target Performance Profiles for Dosage Form Design

    Patrick Crowley

    Patrick Crowley, Owner and Founder, Callum Consultancy

  • The Importance of Defining the Target  
  • Novel Molecular Entities
  • Enhancing Performance for an existing indication.
  • Fixed Drug Combinations 
  • Drug Repurposing 
  • Personalised Medicines
  • clock

    11:30

    An Investigation of the Polymorphic Transformation of Paracetamol to Develop Solid Dispersions

    Mohammed Maniruzzaman

    Mohammed Maniruzzaman, Research Associate, University Of Greenwich

  • Variable temperature X-ray powder diffraction (VTXRPD) used to exploit suitability as a predictive tool for monitoring the polymorphic transformation of paracetamol (PMOL)
  • PMOL physical mixtures and extruded formulations with polyvinyl caprolactam graft copolymer, Soluplus (SOL) and vinylpyrrolidone-vinyl acetate copolymer grades, VP/VA S630 (VP/VA)
  • The experimental findings
  • clock

    12:10

    Networking Lunch

    clock

    13:30

    Ion Exchange Technology and Applications

    Der-Yang Lee

    Der-Yang Lee, Research Director and Fellow, McNeil/Johnson & Johnson

  • Chemistry and Mechanism of Action
  • Potential Applications and Real World Examples
  • Future Opportunities
     
  • clock

    14:10

    Nanoparticles for intestinal controlled release for drugs with poor solubility and poor permeability

    Bruno Sarmento

    Bruno Sarmento, Affilated Reseracher/Assistant Professor, University Of Porto

  • Pharmaceutical nanomaterials
  • Nanomedicine products
  • Opportunities of nanoparticles in the gastrointestinal tract
  • The value of “nano”
  • Nanonization of API’s
  • Formulation of API’s in nanoparticle delivery systems
  • Passive and Active nanoparticle intestinal target
  • clock

    14:50

    Design and development of Cross-linked siRNA delivery system Based on Bio-reducible PAA Nanoparticles for Gene Silencing

    Muhammad Danish

    Muhammad Danish, Senior Lecturer, University of Nottingham

  • Non-viral siRNA delivery is considered very promising but suffers from many of the in vivo delivery challenges
  • Linear PAAs (polyamidoamines) based on MBA DMEDA has previously been used for DNA delivery but their potential for siRNA delivery has not been described yet as non-viral polyelectrolyte complexes (PECs)
  • Main aims include formulation and characterization of cross-linked siRNA polyplexes using blend of linear PAA nanoparticles with bio-reducible characteristics
  • These PAA nanoparticles have shown complete incorporation of siRNA during gel electrophoresis, produced discrete, well condensed spheres below 100nm in diameter using DLS and TEM techniques and were stable in high salt (750nm) and serum conditions
  • Cross-linked polyplexes using CY-3 labelled siRNA were efficiently internalized by A-549 and HCT 116 cells with endosomal release functionality
  • A remarkable dose dependent GAPDH gene silencing (>90%) efficiency was observed on mRNA level using RT-qPCR with no toxicity evaluated by MTS and LDH assays
  • clock

    15:30

    Afternoon Tea

    clock

    15:50

    Development and characterization of parenteral in situ gelling chitosan/glucose-1-phosphate depot systems

    Stephanie Supper

    Stephanie Supper, Senior Scientist, Novartis Pharmaceuticals

  • Gelation mechanism of chitosan/polyol-phosphate systems: role of the polyol part
  • Glucose-1-Phosphate as a new gelling agent: characterization of the physico-chemical properties and shelf life of chitosan / glucose-1-phosphate thermogelling solutions
  • In vitro release and in vivo biocompatibility studies
  • clock

    16:30

    Solid microparticles from liquid gases: a novel, dense-CO2 - based technology to address oral drug delivery challenges

    Pierandrea Esposito

    Pierandrea Esposito, Associate Director and Co-founder, SiTec PharmaBio

  • Drives for innovation in drug delivery: meeting needs of patient–centric medicine, industrial process simplification and flexibility
  • Dense CO2-based technologies can address challenges in oral drug delivery
  • Variosol® technology case studies: microparticles for improved drug bioavailability; controlled drug release; site-specific delivery
  • Process hybridization: enabling role of dense and liquid gases to improve potential of processes, and expand the range of application
  • clock

    17:10

    Chairman’s Closing Remarks and Close of Day Two

    Joel Richard

    Joel Richard, Vice President Peptides , IPSEN

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.